NCT04599309 is a clinical trial in Cancer, sponsored by University Health Network, Toronto.

Who is sponsoring NCT04599309?

NCT04599309 is sponsored by University Health Network, Toronto.

What condition does NCT04599309 study?

NCT04599309 studies Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer.

Is NCT04599309 still recruiting?

NCT04599309 is currently active, enrolled. Last updated 8 May 2024.

Last reviewed 2024-05-08 · How we verify

NCT04599309

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell Carcinoma

Active, enrolled Last updated 8 May 2024

What this trial tests

trial in Cancer in 35 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 October 2020

Primary endpoint
31 March 2023

31 December 2024

Quick facts

Lead sponsor	University Health Network, Toronto
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	35
Start date	15 October 2020
Primary completion	31 March 2023
Estimated completion	31 December 2024
Sites	1 location across Canada

Conditions studied

Cancer — all drugs for Cancer →
Head and Neck Squamous Cell Carcinoma — all drugs for Head and Neck Squamous Cell Carcinoma →
Head and Neck Cancer — all drugs for Head and Neck Cancer →

Sponsor

University Health Network, Toronto

Who can join

18 and older, any sex, with Cancer or Head and Neck Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research study will include patients with high risk locally advanced head and neck squamous cell carcinoma (LA-HNSCC) of the oral cavity, oropharynx, hypopharynx or larynx and patients that are starting on standard definitive treatment. Patients with both stage III HPV positive and stage III HPV negative will be included. In this study, we aim to evaluate feasibility of ctDNA and/or HPV DNA detection in real time in high-risk LA-HNSCC.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact.
Honoré N, Galot R, van Marcke C, Limaye N, et al · · 2021 · cited 50× · PMID 34771526 · DOI 10.3390/cancers13215364
Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck.
Sanz-Garcia E, Zou J, Avery L, Spreafico A, et al · · 2024 · cited 20× · PMID 38409276 · DOI 10.1038/s41418-024-01272-y
Liquid Biopsy in Head and Neck Cancer: Current Evidence and Future Perspective on Squamous Cell, Salivary Gland, Paranasal Sinus and Nasopharyngeal Cancers.
Cabezas-Camarero S, Pérez-Segura P. · · 2022 · cited 12× · PMID 35740523 · DOI 10.3390/cancers14122858
The Role of ctDNA and Liquid Biopsy in the Diagnosis and Monitoring of Head and Neck Cancer: Towards Precision Medicine.
Nassar SI, Suk A, Nguyen SA, Adilbay D, et al · · 2024 · cited 11× · PMID 39335101 · DOI 10.3390/cancers16183129
The Value of Circulating Tumor HPV DNA in Head and Neck Squamous Cell Cancer: A Review.
Dok R, Nuyts S, Lopez F, Bradford C, et al · · 2025 · PMID 41226001 · DOI 10.3390/diagnostics15212708

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04599309 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 8 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04599309.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing